network member

Minnesota

About Network Member

Currently Enrolling

HCRN-GI18-333

Phase 2 study of novel SEQUEnced immunotherapy (pembrolizumab) with anti-angiogenesis and chemotherapy in advanced gastric and gastroesophageaL junction (GEJ) adenocarcinoma (SEQUEL)

Harry H. Yoon

Cancer areas:Gastric Gastroesophageal Junction

Froedtert & the Medical College of Wisconsin

Mayo Clinic

See clinicaltrials.gov

Currently Enrolling

TBCRC047

Innovative Combination Immunotherapy for Metastatic Triple Negative Breast Cancer (TNBC): A Multicenter, Multi-Arm Translational Breast Cancer Research Consortium Study

Hope Rugo

Cancer areas:Breast

Dana-Farber Cancer Institute

Duke Cancer Institute

Georgetown Lombardi Comprehensive Cancer Center

Mayo Clinic

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

The University of Chicago Medicine Comprehensive Cancer Center

UC San Francisco

University of Alabama at Birmingham Comprehensive Cancer Center

University of North Carolina Lineberger Comprehensive Cancer Center

Vanderbilt-Ingram Cancer Center

See clinicaltrials.gov

Currently Enrolling

BTCRC-HEM15-027

Phase I/II Study of Nivolumab in Combination with Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma: BTCRC-HEM15-027

Veronika Bachanova

Cancer areas:Lymphoma

Masonic Cancer Center, University of Minnesota

University of Iowa Holden Comprehensive Cancer Center

University of Wisconsin Carbone Cancer Center

See clinicaltrials.gov

Enrollment Closed

BTCRC-HN17-111

Phase II Trial of Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma: Big Ten Cancer Research Consortium BTCRC-HN17-111

Manish Patel

Cancer areas:Head and Neck

Masonic Cancer Center, University of Minnesota

Robert H. Lurie Comprehensive Cancer Center of Northwestern University

University of Illinois Cancer Center

University of Iowa Holden Comprehensive Cancer Center

University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center

University of Michigan Rogel Cancer Center

University of Wisconsin Carbone Cancer Center

See clinicaltrials.gov

Currently Enrolling

BTCRC-LUN18-153

A Randomized Phase II Trial of Adjuvant Pembrolizumab Versus Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm

Greg Durm

Cancer areas:Lung

Fred & Pamela Buffett Cancer Center

Indiana University Melvin and Bren Simon Comprehensive Cancer Center

Masonic Cancer Center, University of Minnesota

Moffitt Cancer Center

Penn State Cancer Institute

Providence Cancer Institute

Rutgers Cancer Institute of New Jersey

The Ohio State University

University of Illinois Cancer Center

University of Iowa Holden Comprehensive Cancer Center

University of Virginia Cancer Center

Virginia Commonwealth University

See clinicaltrials.gov

Enrollment Closed

HCRN-MEL16-252

Single Arm Phase II Study of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma (SALVO Study). HCRN: MEL16-252

Robert R. McWilliams

Cancer areas:Melanoma

Fox Chase Cancer Center

Masonic Cancer Center, University of Minnesota

Mayo Clinic

Nebraska Cancer Specialists

Providence Cancer Institute

University of Iowa Holden Comprehensive Cancer Center

See clinicaltrials.gov